SANTA MONICA, Calif. & REDWOOD CITY, Calif.–(BUSINESS WIRE)– Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX), today announced the closing of the companies’ previously announced global strategic collaboration to co-develop and co-commercialize Arcellx’s lead late-stage product candidate, CART-ddBCMA, for the treatment of patients with relapsed or refractory multiple myeloma. Multiple myeloma is an incurable disease for most patients and the need remains for effective, safe and broadly accessible therapies.
Atualmente sendo investigado em um estudo fundamental de Fase 2, o CART-ddBCMA é a terapia de células T da Arcellx utilizando o novo aglutinante sintético da empresa, o D-Domain. A Kite e a Arcellx avançarão e comercializarão conjuntamente o ativo CART-ddBCMA nos EUA, e a Kite comercializará o produto fora dos EUA
Terapia de células T CAR está entre os tratamentos inovadores para certos tipos de câncer de sangue. São mais de 750 em andamento ensaios clínicos in Terapia de células T CAR na China Atualmente. Os pacientes que desejam se inscrever podem entrar em contato Câncer Fax linha de atendimento ao paciente no WhatsApp +91 96 1588 1588 ou email para info@cancerfax.com.
Sobre Arcellx
Arcellx, Inc. is a clinical-stage biotechnology company reimagining cell therapy by engineering innovative immunotherapies for patients with cancer and other incurable diseases. Arcellx believes that cell therapies are one of the forward pillars of medicine and Arcellx’s mission is to advance humanity by developing cell therapies that are safer, more effective, and more broadly accessible. Arcellx’s lead product candidate, CART-ddBCMA, is being developed for the treatment of relapsed or refractory mieloma múltiplo (r/r MM) in a Phase 2 pivotal trial. CART-ddBCMA has been granted Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy designations by the U.S. Food and Drug Administration.
Arcellx is also advancing its dosable and controllable CAR-T therapy, ARC-SparX, through two programs: a Phase 1 study of ACLX-001 for r/r MM, initiated in the second quarter of 2022; and ACLX-002 in relapsed or refractory acute myeloid leukemia and high-risk síndrome mielodisplásica, initiated in the fourth quarter of 2022.
Sobre Kite
Kite, a Gilead Company, is a global biopharmaceutical company based in Santa Monica, California, focused on cell therapy to treat and potentially cure cancer. As the global cell therapy leader, Kite has treated more patients with CAR T-cell therapy than any other company. Kite has the largest in-house cell therapy manufacturing network in the world, spanning process development, vector manufacturing, clinical trial supply, and commercial product manufacturing.
Sobre Gilead Sciences
é uma empresa biofarmacêutica que busca e alcança avanços na medicina há mais de três décadas, com o objetivo de criar um mundo mais saudável para todas as pessoas. A empresa está empenhada em desenvolver medicamentos inovadores para prevenir e tratar doenças potencialmente fatais, incluindo VIH, hepatite viral e cancro. A Gilead opera em mais de 35 países em todo o mundo, com sede em Foster City, Califórnia. A Gilead Sciences adquiriu a Kite em 2017.
